ピルフェニドン
ピルフェニドン
出典: フリー百科事典『ウィキペディア（Wikipedia）』 (2022/04/16 18:40 UTC 版)
ピルフェニドン（Pirfenidone）は、特発性肺線維症（IPF）等の治療に用いられる抗線維化薬である。成長因子分泌抑制やI型・II型プロコラーゲン産生抑制等により肺の線維化を低減させる。商品名ピレスパ。2008年に日本でIPFの治療薬として承認された後、2010年インドで、2011年中国と欧州で、2012年カナダで、2014年米国とメキシコで承認された。メキシコでの適応は肺線維症および肝線維症である。創傷治癒異常に用いるために局所用剤も開発された[2]。
- ^ a b c d “Esbriet 267 mg hard capsules”. electronic Medicines Compendium. Intermune UK & I Ltd (2014年1月3日). 2014年3月6日閲覧。
- ^ “Coadjuvant treatment with surgery and pirfenidone in sever facial trauma due to dog bite.”. The journal of Craniofacial Surgery 24 (2). (March 2013). doi:10.1097/SCS.0b013e31828609cb. PMID 23524776.
- ^ a b c d “ピレスパ錠200mg 添付文書” (2014年3月). 2015年9月5日閲覧。
- ^ a b “FDA approves Esbriet to treat idiopathic pulmonary fibrosis”. FDA (2014年10月15日). 2015年9月5日閲覧。
- ^ a b “EPAR summary for the public pirfenidone”. EMA. 2015年9月5日閲覧。
- ^ “A controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients.”. annals of plastic surgery 68 (1). (january 2012). doi:10.1097/SAP.0b013e31821b6d08. PMID 21659848.
- ^ http://www.kitoscell.com
- ^ Macias-Barragan et al. (2010-09-01). “The multifaceted role of pirfenidone and its novel target.”. Fibrogenesis & Tissue Repair 3:16. doi:10.1186/1755-1536-3-16. PMID 20809935.
- ^ García L, Hernández I, Sandoval A, et al. (2002-12). “Pirfenidone effectively reverses experimental liver fibrosis.”. Journal of Hepatology 37 (6): 797-805. doi:10.1016/S0168-8278(02)00272-6. PMID 12445421.
- ^ a b c d e f g h i j k l “Esbriet 267 mg hard capsules”. Summary of product characteristics. European Medicines Agency. 2015年9月5日閲覧。
- ^ a b c Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K (June 2011). “Antifibrotic activities of pirfenidone in animal models”. Eur Respir Rev 20 (120): 85–97. doi:10.1183/09059180.00001111. PMID 21632796.
- ^ a b c Di Sario A, Bendia E, Svegliati Baroni G, Ridolfi F, Casini A, Ceni E, Saccomanno S, Marzioni M, Trozzi L, Sterpetti P, Taffetani S, Benedetti A (November 2002). “Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production”. J. Hepatol. 37 (5): 584–91. doi:10.1016/S0168-8278(02)00245-3. PMID 12399223.
- ^ a b Hewitson TD, Kelynack KJ, Tait MG, Martic M, Jones CL, Margolin SB, Becker GJ (2001). “Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis”. J. Nephrol. 14 (6): 453–60. PMID 11783601.
- ^ a b Lin X, Yu M, Wu K, Yuan H, Zhong H (August 2009). “Effects of pirfenidone on proliferation, migration, and collagen contraction of human Tenon's fibroblasts in vitro”. Invest. Ophthalmol. Vis. Sci. 50 (8): 3763–70. doi:10.1167/iovs.08-2815. PMID 19264889.
- ^ Lee BS, Margolin SB, Nowak RA (January 1998). “Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production”. J. Clin. Endocrinol. Metab. 83 (1): 219–23. doi:10.1210/jc.83.1.219. PMID 9435445.
- ^ Ozes ON, Blatt LM (2006). “Development of a high throughput collagen assay using a cellular model of idiopathic pulmonary fibrosis”. Chest 130: 230S. doi:10.1378/chest.130.4_meetingabstracts.230s-a.
- ^ a b Sulfab M (2007). “The effects of pirfenidone and IFN-inducible T-cell alpha chemoattractant (ITAC) on transforming-growth factor-beta 1-mediated synthesis of extracellular matrix proteins in endothelial cells”. Am J Respir Crit Care Med 175: A730.
- ^ Nakayama S, Mukae H, Sakamoto N, Kakugawa T, Yoshioka S, Soda H, Oku H, Urata Y, Kondo T, Kubota H, Nagata K, Kohno S (January 2008). “Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts”. Life Sci. 82 (3–4): 210–7. doi:10.1016/j.lfs.2007.11.003. PMID 18093617.
- ^ Phillips R, Wang T, Blatt LM, Seiwert S (2005). “Pirfenidone mediates differential effects on lipopolysaccharide-induced cytokine expression in human peripheral mononuclear cells”. Chest 128. doi:10.1378/chest.128.4_meetingabstracts.169s-a.
- ^ Grattendick KJ, Nakashima JM, Feng L, Giri SN, Margolin SB (May 2008). “Effects of three anti-TNF-alpha drugs: etanercept, infliximab and pirfenidone on release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro”. Int. Immunopharmacol. 8 (5): 679–87. doi:10.1016/j.intimp.2008.01.013. PMID 18387510.
- ^ a b c Kakugawa T, Mukae H, Hayashi T, Ishii H, Abe K, Fujii T, Oku H, Miyazaki M, Kadota J, Kohno S (July 2004). “Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis”. Eur. Respir. J. 24 (1): 57–65. doi:10.1183/09031936.04.00120803. PMID 15293605.
- ^ a b c Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A, Matsushima S, Torii M, Arimura A (August 2008). “Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis”. Eur. J. Pharmacol. 590 (1–3): 400–8. doi:10.1016/j.ejphar.2008.06.046. PMID 18598692.
- ^ a b Card JW, Racz WJ, Brien JF, Margolin SB, Massey TE (September 2003). “Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity”. Toxicol. Sci. 75 (1): 169–80. doi:10.1093/toxsci/kfg167. PMID 12832656.
- ^ Liu H, Drew P, Gaugler AC, Cheng Y, Visner GA (June 2005). “Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway”. Am. J. Transplant. 5 (6): 1256–63. doi:10.1111/j.1600-6143.2005.00876.x. PMID 15888029.
- ^ a b Hirano A, Kanehiro A, Ono K, Ito W, Yoshida A, Okada C, Nakashima H, Tanimoto Y, Kataoka M, Gelfand EW, Tanimoto M (September 2006). “Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge”. Am. J. Respir. Cell Mol. Biol. 35 (3): 366–77. doi:10.1165/rcmb.2005-0452OC. PMC 2643289. PMID 16675785.
- ^ Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, Giri SN (June 1995). “Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters”. J. Lab. Clin. Med. 125 (6): 779–85. PMID 7539478.
- ^ Iyer SN, Margolin SB, Hyde DM, Giri SN (1998). “Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model”. Exp. Lung Res. 24 (1): 119–32. doi:10.3109/01902149809046058. PMID 9457473.
- ^ Iyer SN, Gurujeyalakshmi G, Giri SN (April 1999). “Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis”. J. Pharmacol. Exp. Ther. 289 (1): 211–8. PMID 10087006.
- ^ Lee KW, Everett TH, Rahmutula D, Guerra JM, Wilson E, Ding C, Olgin JE (October 2006). “Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure”. Circulation 114 (16): 1703–12. doi:10.1161/CIRCULATIONAHA.106.624320. PMC 2129103. PMID 17030685.
- ^ Nguyen DT, Ding C, Wilson E, Marcus GM, Olgin JE (October 2010). “Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias”. Heart Rhythm 7 (10): 1438–45. doi:10.1016/j.hrthm.2010.04.030. PMID 20433946.
- ^ Mirkovic S, Seymour AM, Fenning A, Strachan A, Margolin SB, Taylor SM, Brown L (February 2002). “Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats”. Br. J. Pharmacol. 135 (4): 961–8. doi:10.1038/sj.bjp.0704539. PMC 1573203. PMID 11861324.
- ^ Shimizu T, Kuroda T, Hata S, Fukagawa M, Margolin SB, Kurokawa K (July 1998). “Pirfenidone improves renal function and fibrosis in the post-obstructed kidney”. Kidney Int. 54 (1): 99–109. doi:10.1046/j.1523-1755.1998.00XXX.x. PMID 9648068.
- ^ Takakuta K, Fujimori A, Chikanishi T, Tanokura A, Iwatsuki Y, Yamamoto M, Nakajima H, Okada M, Itoh H (March 2010). “Renoprotective properties of pirfenidone in subtotally nephrectomized rats”. Eur. J. Pharmacol. 629 (1–3): 118–24. doi:10.1016/j.ejphar.2009.12.011. PMID 20006961.
- ^ Salazar-Montes A, Ruiz-Corro L, López-Reyes A, Castrejón-Gómez E, Armendáriz-Borunda J (October 2008). “Potent antioxidant role of pirfenidone in experimental cirrhosis”. Eur. J. Pharmacol. 595 (1–3): 69–77. doi:10.1016/j.ejphar.2008.06.110. PMID 18652820.
- ^ García L, Hernández I, Sandoval A, Salazar A, Garcia J, Vera J, Grijalva G, Muriel P, Margolin S, Armendariz-Borunda J (December 2002). “Pirfenidone effectively reverses experimental liver fibrosis”. J. Hepatol. 37 (6): 797–805. doi:10.1016/S0168-8278(02)00272-6. PMID 12445421.
- ^ a b Taniguchi H, Ebina M, Kondoh Y, et al. (April 2010). “Pirfenidone in idiopathic pulmonary fibrosis”. Eur. Respir. J. 35 (4): 821–9. doi:10.1183/09031936.00005209. PMID 19996196.
- ^ a b c Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM (May 2011). “Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials”. Lancet 377 (9779): 1760–9. doi:10.1016/S0140-6736(11)60405-4. PMID 21571362.
- ^ King TE Jr, Bradford WZ, Castro-Bernardini S, et al. (2014-05-29). “A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.”. N Engl J Med. 370 (29): 2083-92. doi:10.1056/NEJMoa1402582. PMID 24836312.
- ^ a b Spagnolo P, Del Giovane C, Luppi F, Cerri S, Balduzzi S, Walters EH, D'Amico R, Richeldi L (2010). “Non-steroid agents for idiopathic pulmonary fibrosis”. Cochrane Database Syst Rev (9): CD003134. doi:10.1002/14651858.CD003134.pub2. PMID 20824834.
- ^ “厚労省 ピレスパ錠やサレドカプセルが正式承認”. ミクス (2008年10月16日). 2015年9月5日閲覧。
- ^ “China SFDA Approves F647/pirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis”. Press Release. EvaluatePharma (2011年9月22日). 2015年9月5日閲覧。
- ^ kitoscelllp.com
- ^ “Coadjuvant treatment with surgery and pirfenidone in sever facial trauma due to dog bite.”. The journal of Craniofacial Surgery 24 (2). (March 2013). doi:10.1097/SCS.0b013e31828609cb. PMID 23524776.
- ^ Frieden J (2010年5月10日). “FDA Nixes Pirfenidone for Now, Wants New Trial”. MedPage Today. 2015年9月5日閲覧。
- ^ “Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)”. NCT01366209. U.S. National Institutes of Health: ClinicalTrials.gov. 2015年9月5日閲覧。
[続きの解説]
「ピルフェニドン」の続きの解説一覧
- ピルフェニドンのページへのリンク
